Neuroendocrine differentiated small cell carcinoma presenting as recurrent prostate cancer after androgen deprivation therapy

2001 ◽  
Vol 88 (9) ◽  
pp. 982-983 ◽  
Author(s):  
Y. Miyoshi ◽  
H. Uemura ◽  
K. Kitami ◽  
Y. Satomi ◽  
Y. Kubota ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cell Carcinoma ◽  
Small Cell Carcinoma ◽  
Androgen Deprivation Therapy ◽  
Small Cell ◽  
Androgen Deprivation ◽  
Recurrent Prostate Cancer

scholarly journals Small Cell Carcinoma of the Prostate in an Elderly Patient: A Case Report and Review of the Literature

Rare Tumors ◽  
2016 ◽  
Vol 8 (4) ◽  
pp. 176-178 ◽  
Author(s):  
Dale Alan Whitaker ◽  
Daniel H. Miller ◽  
Niveditha Jagadesh ◽  
Gerald W. Strong ◽  
Lauren Hintenlang ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Radiation Therapy ◽  
Cell Carcinoma ◽  
Small Cell Carcinoma ◽  
Current Knowledge ◽  
Case Reports ◽  
The United States ◽  
Small Cell ◽  
Rapid Progression ◽  
Retrospective Case

Prostate cancer is the most common malignancy of men in the United States. Small-cell carcinoma (SCC), which typically presents as an aggressive lung malignancy, is a rare diagnosis within the setting of prostate cancer pathology. Due to its limited prevalence, little information regarding the treatment and prognosis of this disease in large populations is available. To date our current knowledge base is largely limited to case reports and retrospective case reviews. The mainstay of treatment for this particular histology most often involves a multimodality approach utilizing chemotherapy in conjunction with radiation therapy, androgen deprivation therapy, or prostatectomy. Here we present the case of an elderly 89-year-old Caucasian male who was diagnosed with SCC of the prostate. Despite proceeding with a course of definitive radiotherapy, the patient experienced rapid progression of disease and ultimately elected to discontinue radiation therapy and receive hospice care.

scholarly journals Detection Rate of 68Ga-PSMA Ligand PET/CT in Patients with Recurrent Prostate Cancer and Androgen Deprivation Therapy

Biomedicines ◽  
2020 ◽  
Vol 8 (11) ◽  
pp. 511
Author(s):  
Joachim Brumberg ◽  
Melanie Beckl ◽  
Alexander Dierks ◽  
Andreas Schirbel ◽  
Markus Krebs ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Androgen Deprivation Therapy ◽  
Detection Rate ◽  
Androgen Deprivation ◽  
Disease Stage ◽  
Whole Body ◽  
Recurrent Prostate Cancer ◽  
Detection Rates ◽  
Psma Ligand ◽  
Pet Ct

Prostate-specific membrane antigen (PSMA) ligand PET/CT enables the localization of tumor lesions in patients with recurrent prostate cancer, but it is unclear whether androgen deprivation therapy (ADT) influences diagnostic accuracy. The aim of this study was to evaluate the effect of ADT on the detection rate of 68Ga-PSMA ligand PET/CT. Thus, 399 patients with initial radical prostatectomy and 68Ga-PSMA ligand PET/CT during PSA relapse were retrospectively evaluated. Propensity score matching was used to create two balanced groups of 62 subjects who either did or did not receive ADT within six months before imaging. All 68Ga-PSMA ligand PET/CT were evaluated visually and with semiquantitative measures. The detection rate of tumor recurrence was significantly higher in the group with ADT (88.7% vs. 72.6%, p = 0.02) and improved with increasing PSA-levels in both groups. In subjects with pathological PET/CT and ADT, whole-body total lesion PSMA (p < 0.01) and PSMA-derived tumor volume (p < 0.01) were significantly higher than in those without ADT. More PSMA-positive lesions and higher PSMA-derived volumetric parameters in patients with ADT suggest that a better detection rate is related to a (biologically) more advanced disease stage. Due to high detection rates in patients with PSA-levels < 2 ng/mL, the withdrawal of ADT before PSMA ligand PET/CT cannot be recommended.

scholarly journals Not such a small diagnosis: small cell carcinoma of the prostate

2020 ◽  
Vol 2020 (6) ◽  
Author(s):  
Abdul Rauf ◽  
Stephanie F Smith ◽  
Rono Mukherjee ◽  
Nyla Nasir
Keyword(s):  
Prostate Cancer ◽  
Cell Carcinoma ◽  
Small Cell Carcinoma ◽  
Targeted Therapies ◽  
Specific Antigen ◽  
Serum Levels ◽  
Prostate Adenocarcinoma ◽  
Small Cell ◽  
Neck Swelling ◽  
Genomic Typing

Abstract Small cell carcinoma (SCC) is an aggressive malignancy most commonly described in the lung. We present a case of a 61-year-old male who presented with a neck swelling and was subsequently found to have metastatic SCC of the prostate. Clinicians should be aware that it metastasizes early. Unlike conventional prostate adenocarcinoma, it is not a prostate-specific antigen (PSA) secreting tumor hence serum levels do not correlate with disease severity, and a low PSA reading may give false reassurance. In the future, further studies on genomic typing and novel targeted therapies may achieve better clinical outcomes for patients with this aggressive type of prostate cancer.

Primary genitourinary small cell carcinoma: Clinicopathologic and survival outcomes from SEER database.

2011 ◽  
Vol 29 (7_suppl) ◽  
pp. 200-200
Author(s):  
R. Thota ◽  
S. Birdsong ◽  
S. Subbiah
Keyword(s):  
Prostate Cancer ◽  
Bladder Cancer ◽  
Cell Carcinoma ◽  
Small Cell Carcinoma ◽  
Renal Cancer ◽  
Small Cell ◽  
External Beam Radiation ◽  
Seer Database ◽  
Specific Mortality ◽  
Cancer Specific Mortality

200 Background: Small cell carcinoma of genitourinary system (SCC) is a highly aggressive and rare entity. The aim of the study is to characterize the clinicopathologic characteristics and evaluate the treatment outcomes of SCC in adult patients. Methods: Retrospective analysis of 732 patents diagnosed with small cell carcinoma of bladder from 1973 to 2007 was done via SEER database. Demographics, stage, type of treatment received and cancer-specific mortality were examined. Results: 732 patients were identified with SCC of genitourinary tract of which 341 were small cell bladder cancer, 336 were small cell prostate cancer and 55 were small cell renal cancer. Of these 644 patients were males and 88 were females. Median age of diagnosis is 73 years for bladder, 72 years for prostate and 70 years for renal cancer. Majority of the patients were Caucasians (89%) followed by African Americans (6%) and other races (4.98%). Grading of the tumor revealed that 12 patients had well differentiated tumor, 18 patients had moderately differentiated tumor, 191 patients had poorly differentiated, 292 patients had undifferentiated tumor and 219 patients had unknown grade. Pathological T-stages were as follows: T1= 34 (4.6%), T2= 102 (14%), T3= 43 (9%), T4= 41 (5.6%), 38.4% unknown T stage and 67 (9%) patients had metastatic disease. In majority of the patients the treatment received was unknown (565), 90 patients received external beam radiation, and 76 patients received surgery. Cancer-specific mortality was 54% in bladder cancer, 71% in prostate cancer and 78.6% in renal cancer. Median overall survival for all stages was 15.8 months in bladder cancer, 11.3 months in prostate cancer and 8 months in renal cancer. Conclusions: Results show that SCC is a highly aggressive tumor with poor prognosis. Clinical trials involving multiple institutes are needed to accrue enough patients so that treatment paradigms for this uncommon disease can be developed. No significant financial relationships to disclose.

Sign in / Sign up

Export Citation Format

Share Document